RXSIGHT INC (RXST) Fundamental Analysis & Valuation

NASDAQ:RXST • US78349D1072

Current stock price

6.09 USD
-0.17 (-2.72%)
At close:
6.09 USD
0 (0%)
After Hours:

This RXST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. RXST Profitability Analysis

1.1 Basic Checks

  • RXST had negative earnings in the past year.
  • RXST had a negative operating cash flow in the past year.
  • RXST had negative earnings in each of the past 5 years.
  • In the past 5 years RXST always reported negative operating cash flow.
RXST Yearly Net Income VS EBIT VS OCF VS FCFRXST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M -20M -40M -60M

1.2 Ratios

  • RXST has a Return On Assets of -12.49%. This is comparable to the rest of the industry: RXST outperforms 57.98% of its industry peers.
  • Looking at the Return On Equity, with a value of -14.13%, RXST is in the better half of the industry, outperforming 65.43% of the companies in the same industry.
Industry RankSector Rank
ROA -12.49%
ROE -14.13%
ROIC N/A
ROA(3y)-15.91%
ROA(5y)-23.49%
ROE(3y)-18.07%
ROE(5y)-32.74%
ROIC(3y)N/A
ROIC(5y)N/A
RXST Yearly ROA, ROE, ROICRXST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100

1.3 Margins

  • The Gross Margin of RXST (76.60%) is better than 87.77% of its industry peers.
  • In the last couple of years the Gross Margin of RXST has grown nicely.
  • RXST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.74%
GM growth 5Y45.74%
RXST Yearly Profit, Operating, Gross MarginsRXST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 1K -1K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. RXST Health Analysis

2.1 Basic Checks

  • RXST does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RXST has been increased compared to 1 year ago.
  • RXST has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, RXST has an improved debt to assets ratio.
RXST Yearly Shares OutstandingRXST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
RXST Yearly Total Debt VS Total AssetsRXST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 2.25 indicates that RXST is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • RXST has a better Altman-Z score (2.25) than 65.43% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that RXST is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.00, RXST is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.25
ROIC/WACCN/A
WACC10.63%
RXST Yearly LT Debt VS Equity VS FCFRXST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 10.95 indicates that RXST has no problem at all paying its short term obligations.
  • The Current ratio of RXST (10.95) is better than 94.15% of its industry peers.
  • A Quick Ratio of 9.75 indicates that RXST has no problem at all paying its short term obligations.
  • RXST has a Quick ratio of 9.75. This is amongst the best in the industry. RXST outperforms 93.09% of its industry peers.
Industry RankSector Rank
Current Ratio 10.95
Quick Ratio 9.75
RXST Yearly Current Assets VS Current LiabilitesRXST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. RXST Growth Analysis

3.1 Past

  • The earnings per share for RXST have decreased strongly by -31.94% in the last year.
  • The Revenue has decreased by -3.89% in the past year.
  • The Revenue has been growing by 55.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-31.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.67%
Revenue 1Y (TTM)-3.89%
Revenue growth 3Y40%
Revenue growth 5Y55.73%
Sales Q2Q%-18.92%

3.2 Future

  • RXST is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.60% yearly.
  • RXST is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.94% yearly.
EPS Next Y-34.19%
EPS Next 2Y-5.17%
EPS Next 3Y-1.6%
EPS Next 5YN/A
Revenue Next Year-1.76%
Revenue Next 2Y3.75%
Revenue Next 3Y4.94%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
RXST Yearly Revenue VS EstimatesRXST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
RXST Yearly EPS VS EstimatesRXST Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. RXST Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RXST. In the last year negative earnings were reported.
  • Also next year RXST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXST Price Earnings VS Forward Price EarningsRXST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXST Per share dataRXST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.17%
EPS Next 3Y-1.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RXST Dividend Analysis

5.1 Amount

  • RXST does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RXST Fundamentals: All Metrics, Ratios and Statistics

RXSIGHT INC

NASDAQ:RXST (3/30/2026, 8:00:02 PM)

After market: 6.09 0 (0%)

6.09

-0.17 (-2.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-25
Earnings (Next)N/A
Inst Owners89.97%
Inst Owner Change9.14%
Ins Owners5.51%
Ins Owner Change0.5%
Market Cap251.33M
Revenue(TTM)134.48M
Net Income(TTM)-38.94M
Analysts52.5
Price Target10.26 (68.47%)
Short Float %14.3%
Short Ratio5.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.49%
Min EPS beat(2)35.1%
Max EPS beat(2)37.88%
EPS beat(4)3
Avg EPS beat(4)16.38%
Min EPS beat(4)-16.68%
Max EPS beat(4)37.88%
EPS beat(8)7
Avg EPS beat(8)18.82%
EPS beat(12)11
Avg EPS beat(12)20.92%
EPS beat(16)15
Avg EPS beat(16)19.42%
Revenue beat(2)2
Avg Revenue beat(2)11.91%
Min Revenue beat(2)6.15%
Max Revenue beat(2)17.67%
Revenue beat(4)2
Avg Revenue beat(4)3.75%
Min Revenue beat(4)-6.3%
Max Revenue beat(4)17.67%
Revenue beat(8)4
Avg Revenue beat(8)2.81%
Revenue beat(12)8
Avg Revenue beat(12)3.36%
Revenue beat(16)12
Avg Revenue beat(16)4.99%
PT rev (1m)-3.14%
PT rev (3m)-2.62%
EPS NQ rev (1m)-7.61%
EPS NQ rev (3m)-20.94%
EPS NY rev (1m)-12.88%
EPS NY rev (3m)-26.06%
Revenue NQ rev (1m)-5.29%
Revenue NQ rev (3m)-3.33%
Revenue NY rev (1m)-4.5%
Revenue NY rev (3m)-4.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.87
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-0.95
EYN/A
EPS(NY)-1.27
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS3.26
BVpS6.68
TBVpS6.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -12.49%
ROE -14.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.6%
FCFM N/A
ROA(3y)-15.91%
ROA(5y)-23.49%
ROE(3y)-18.07%
ROE(5y)-32.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.74%
GM growth 5Y45.74%
F-Score3
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 117.27%
Cap/Sales 2.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.95
Quick Ratio 9.75
Altman-Z 2.25
F-Score3
WACC10.63%
ROIC/WACCN/A
Cap/Depr(3y)126.95%
Cap/Depr(5y)97.78%
Cap/Sales(3y)4.05%
Cap/Sales(5y)5.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.67%
EPS Next Y-34.19%
EPS Next 2Y-5.17%
EPS Next 3Y-1.6%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.89%
Revenue growth 3Y40%
Revenue growth 5Y55.73%
Sales Q2Q%-18.92%
Revenue Next Year-1.76%
Revenue Next 2Y3.75%
Revenue Next 3Y4.94%
Revenue Next 5YN/A
EBIT growth 1Y-30.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.87%
EBIT Next 3Y-5.36%
EBIT Next 5YN/A
FCF growth 1Y13.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.46%
OCF growth 3YN/A
OCF growth 5YN/A

RXSIGHT INC / RXST Fundamental Analysis FAQ

What is the ChartMill fundamental rating of RXSIGHT INC (RXST) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RXST.


What is the valuation status for RXST stock?

ChartMill assigns a valuation rating of 0 / 10 to RXSIGHT INC (RXST). This can be considered as Overvalued.


Can you provide the profitability details for RXSIGHT INC?

RXSIGHT INC (RXST) has a profitability rating of 2 / 10.


How financially healthy is RXSIGHT INC?

The financial health rating of RXSIGHT INC (RXST) is 5 / 10.


What is the earnings growth outlook for RXSIGHT INC?

The Earnings per Share (EPS) of RXSIGHT INC (RXST) is expected to decline by -34.19% in the next year.